Latest Regulatory Clearance News

Aura Consolidated Group and Qoria Limited have announced a merger to create AXQ, a global leader in digital safety and cybersecurity, backed by a US$75 million equity raise and targeting strong growth and innovation.

FireFly Metals has agreed to sell its Ontario gold assets to Bellavista Resources for up to A$86.1 million in shares and performance rights, unlocking value for shareholders while focusing on its copper-gold growth strategy.

FireFly Metals has agreed to sell its Ontario gold assets, including a 70% stake in the Pickle Crow Project, to Bellavista Resources for up to A$86.1 million in scrip. FireFly shareholders will receive Bellavista shares, maintaining exposure to the assets while FireFly focuses on its copper-gold ambitions.

Global Uranium and Snow Lake Resources have agreed to a binding merger scheme, with Snow Lake acquiring all remaining shares of Global Uranium. This follows a major drilling success at the Pine Ridge Uranium Project and regulatory approvals that pave the way for a combined uranium-focused entity.

Toro Energy shareholders are set to gain exposure to a diversified uranium portfolio through IsoEnergy’s acquisition offer at a near 80% premium, while Toro advances its Wiluna Uranium Project amid strong market tailwinds.

Echelon Resources reported a slight dip in production but secured long-term gas sales contracts extending to 2034 and plans four new development wells in the Amadeus Basin. The company also reduced its debt by A$7 million, maintaining financial flexibility for growth.

Zeus Resources has made significant progress in its December quarter activities, advancing trenching at the Casablanca Antimony Project and confirming gold and lithium anomalies at Blue Hill. The company also reported stable cash reserves and key corporate developments following its 2025 AGM.

ReNerve Limited reported a robust 80% increase in quarterly sales driven by strong US market adoption and expanded hospital approvals. The company advances its nerve repair product pipeline with key regulatory milestones and a refreshed board.

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.

Medical Developments International has posted positive operating cashflow for the first half of FY26, driven by robust growth in its flagship product Penthrox across Australia and Europe, alongside progress in paediatric approvals.

Imricor Medical Systems has achieved a major milestone with FDA clearance for its NorthStar Mapping System, the first MRI-native 3D cardiac mapping platform approved in the US. This approval positions Imricor at the forefront of MRI-guided cardiac procedures in the world’s largest electrophysiology market.